Article Text

Download PDFPDF

Monitoring of suicide risk throughout the course of treatment with antidepressants for depression is required, but vigilance is required for those on some particular antidepressant agents
  1. Sarah Hetrick
  1. University of Melbourne, Centre for Youth Mental Health and Orygen, Melbourne, Victoria, Australia;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

ABSTRACT FROM: Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 2015;350:h517.

What is already known on this topic

Evidence of an increase in suicidal behaviours in children and adolescents prescribed antidepressants resulted in a Food and Drug Administration (FDA) ‘black box’ warning in 2004 for this age group. This was extended to young adults up to the age of 24 years in 2007. A link with suicide has not been clearly demonstrated for any age group, nor have differences in the risk of these behaviours according to the type of antidepressant. Large cohort studies overcome the limitations of trials to establish these links and while not clearly demonstrating differences in risk according to the class of antidepressant, there is emerging evidence of an increased risk according to the individual agent, …

View Full Text


  • Competing interests SH is the lead author on the Cochrane systematic review on antidepressants for child and adolescent depression.